

EXECUTIVE SUMMARY

THE ECONOMIC IMPACT OF GENOME BC

BACKGROUND

Genome BC is a not-for-profit organization supporting world-class genomics research projects, technology platforms and innovation initiatives with the aim of growing a globally competitive life sciences sector and delivering sustainable benefits for British Columbia, Canada and beyond.

By connecting academic researchers, industry partners, and public sector interests, it advances research and innovation collaborations, invests in promising start-up companies, and catalyzes partnerships to drive societal, environmental, and economic benefits for BC.


Since 2000, Genome BC has managed a cumulative portfolio of nearly \$1.3B in over 500 research projects, technology platforms, and innovation initiatives that are improving the lives of people every day through advances in health care, forestry, fisheries and aquaculture, agrifoods and agriculture, mining and energy, and environmental stewardship.

ECONOMIC IMPACT ANALYSIS

Genome BC's investments in projects and associated platforms, as well as its centre operations, create economic activity within BC which in turn generates GDP, employment, and tax revenues for all levels of government. In addition, economic impacts are enabled through the spending of additional funds leveraged from other sources as a result of Genome BC's initial investment in projects and associated platforms.

These expenditures create economic impacts at the direct, indirect and induced levels. Direct impacts arise from the initial spending on operating and project related activities while indirect and induced impacts arise from linkages that exist with suppliers and service providers, as well as through the ripple effects of their spending within the economy.

CATEGORIES OF ECONOMIC IMPACTS



GENOME BC'S ECONOMIC IMPACTS FROM 2000-2026

The table below summarizes the total estimated economic impacts throughout Genome BC's Strategic Plans I, II, III, IV^{\dagger} , V and the Financial Plan VI by category.

| | Total Output (Millions) | Total GDP (Millions) | Total Employment (FTEs) | Total Government Taxes (Millions) |
|--|-----------------------------------|--------------------------------|-------------------------------|--|
| Economic Impacts of Genome BC in Strate | gic Plans I, II, III | and IV | · | |
| Created by Centre Operations | \$172.0 | \$144.4 | 1,535 | \$28.4 |
| Created by Investments and Co-Investments in Projects and Platforms | \$1,170.1 | \$994.5 | 13,343 | \$191.4 |
| Created by Investments and Co-Investments in SMEs | \$25.3 | \$17.9 | 180 | \$3. |
| Enabled by Investments and Co-Investments in Projects and Platforms | \$1,132.8 | \$956.0 | 12,064 | \$184. |
| Enabled by Investments and Co-Investments in SMEs | \$609.7 | \$431.3 | 4,348 | \$88. |
| Enabled by Investments and Co-Investments in SMEs through the I ² Program | \$52.2 | \$35.8 | 372 | \$7. |
| Total Strategic Plans I, II, III and IV | \$3,162.0 | \$2,579.9 | 32,382 | \$504. |
| Economic Impacts of Genome BC in Strate | gic Plan V and t | he Financial P | lan VI | |
| Created by Centre Operations | \$147.4 | \$93.5 | 610 | \$20. |
| Created by Investments and Co-Investments in Projects and Platforms | \$372.8 | \$262.7 | 2,330 | \$56. |
| Created by Investments and Co-Investments in Programs Supporting SMEs | \$23.0 | \$16.5 | 130 | \$3. |
| Enabled by Investments and Co-Investments in Projects and Platforms | \$490.4 | \$347.7 | 2,990 | \$75. |
| Enabled by Investments and Co-Investments in Programs Supporting SMEs | \$2,115.9 | \$1,523.4 | 12,070 | \$324. |
| Enabled by Investments and Co-Investments in SMEs through the I ² Program | \$149.7 | \$97.0 | 970 | \$21. |
| Total Strategic Plan V and the Financial Plan VI | \$3,299.2 | \$2,340.8 | 19,100 | \$501. |
| Total | \$6,435.3 | \$4,920.7 | 51,482 | \$1,006. |

[†]Please note that the economic impacts developed for Strategic Plan IV reported in the 2018 study included forecasted expenditures and investments for the fiscal years 2018/19 and 2019/20. The impacts associated with Strategic Plan IV reported here have been adjusted based on the actual expenditures and investments observed for the fiscal years 2018/19 and 2019/20.

